Logo image
A morpholino oligomer therapy regime that restores mitochondrial function and prevents mdx cardiomyopathy
Journal article   Open access   Peer reviewed

A morpholino oligomer therapy regime that restores mitochondrial function and prevents mdx cardiomyopathy

H.M. Viola, V.P.A. Johnstone, A.M. Adams, S. Fletcher and L.C. Hool
JACC: Basic to Translational Science, Vol.3(3), pp.391-402
2018
pdf
morpholino.pdfDownloadView
Published (Version of Record) Open Access
url
Free to Read *No subscription requiredView

Abstract

Current clinical trials demonstrate Duchenne muscular dystrophy (DMD) patients receiving phosphorodiamidate morpholino oligomer (PMO) therapy exhibit improved ambulation and stable pulmonary function; however, cardiac abnormalities remain. Utilizing the same PMO chemistry as current clinical trials, we have identified a non-toxic PMO treatment regimen that restores metabolic activity and prevents DMD cardiomyopathy. We propose that a treatment regimen of this nature may have the potential to significantly improve morbidity and mortality from DMD by improving ambulation, stabilizing pulmonary function, and preventing the development of cardiomyopathy.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

84 File views/ downloads
86 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.255 Musculoskeletal Disorders
1.255.628 Duchenne Muscular Dystrophy
Web Of Science research areas
Cardiac & Cardiovascular Systems
ESI research areas
Clinical Medicine
Logo image